45results about How to "Enhance humoral immune response" patented technology

The invention provides human interleukin interleukin-2 (IL-2)/Fc fusion protein. The human IL-2 of the fusion protein comprises all sequences of a human IL-2 extracellular region; the Fc fragments comprise a hinge region, a CH2 region and a CH3 region; the human IL-2/Fc sequences are fused directly or through a connection sequence; and the Fc fragments are human or animal IgG, IgM, IgD and IgA orsubtypes thereof. The ADCC and CDC effective factor action can be eliminated, and in addition, the human IL-2/Fc fusion protein has the compatibility with a recombinant IL-2 receptor so that the half-life period is obviously prolonged and also has all the biological activity of the IL-2 receptor. The IL-2/Fc obviously improves the humoral immune response stimulated by the hepatitis B vaccine and the immunity of the CD8+T cells targeted to the hepatitis B vaccine. Moreover, the balance immune (suppression) of the effective T cells and the regulatory t cells can be adjusted under the action of the cyclosporine A so that the pancreatic islet transplantation immune tolerance is induced.

The present invention features methods and compositions related to chitosan antigen depots, and chitosan cytokine depots, and the use of depot compositions in treating and preventing diseases.

The present invention discloses an application of ginseng total saponin or monomer saponin Rb1 as vaccine immunologic adjuvant. The ginseng total saponin or monomer saponin Rb1 and aluminium hydroxide are mixed and used as vaccine immunologic adjuvant, and as compared with traditional aluminium hydroxide adjuvant said invention possesses the following advantages: (1) its side effect is less; (2) said vaccine can be stored under the condition of frozen low-temp. and it can prolong effective period of vaccine; (3) its method is simple and convenient, its quality is easy to be controlled; and (4) it can induce body to produce higher humoral immunity response.

The invention provides a novel tuberculosis mycobacterium subunit vaccine containing unite adjuvant, which takes Ag85b protein, ESAT 6-CFP10 fusion protein as antigen component, and aluminum and PolyIC as a composite adjuvant. The adjuvant provided by the invention can effectively improve cellular immunity response of body to the tuberculosis subunit vaccine; at the same time, the adjuvant combines with the tuberculosis mycobacterium antigen Ag85b protein, ESAT6-CFP10 fusion protein, therefore the immunization effect is better than the compatibility effect of using other single adjuvant component and Ag85b protein and ESAT6-CFP10 fusion protein.

The present invention relates to the field of prevention and treatment of disorders associated with the occurrence of certain carbohydrate epitopes. More particularly, the present invention relates to the prevention and treatment of carbohydrate epitope positive tumors. It relates to formulations and methods for the induction of an effective carbohydrate specific cellular immune response.

The invention discloses a purifying method of a methicillin-resistant staphylococcus aureus MRSA recombinant protein vaccine I1C, wherein the I1C protein is obtained by recombining and fusing active functional fragments of two antigen molecules of IsdB and ClfA of methicillin-resistant staphylococcus aureus and expressing escherichia coli genetically engineered bacteria. The high purity MRSA recombinant dual subunit genetic engineering protein I1C is obtained by technologies on the genetically engineered bacteria such as high pressure breaking, salting out, GST (Glutathione S Transferase) affinity chromatography, PP (Prescission Protease) digestion, adhere chromatography, gel filtration chromatography and the like. The method disclosed by the invention is simple and rapid in purifying process, easiness in application and good in repeatability. The target protein obtained is high in purity. Animal tests verify that the vaccine can effectively stimulate the organism to generate higher humoral immune response and good immunoprotection.

The present invention provides methods for producing antibodies against peptides, proteins, or such to which immune tolerance is easily established, by using antigen-binding molecules comprising a domain that binds to a molecule expressed on the surface of a cell having an immune response-suppressing function and a T cell receptor (TCR) complex-binding domain. The present invention also provides pharmaceutical compositions for use in combination with therapeutic vaccines and agents for enhancing a humoral immune response, each comprising the antigen-binding molecules as active ingredients.

The invention discloses a respiratory syncytial virus vaccine, and a preparation method and an application thereof. The active components of the respiratory syncytial virus vaccine comprise a respiratory syncytial virus G protein and an immunosuppressant; the amino acid sequence of the respiratory syncytial virus G protein is represented by sequence 2 in a sequence table; and the immunosuppressant is cyclosporins A. Test proves that the respiratory syncytial virus vaccine can enhance the humoral immunoreaction in the virus neutralizing antibody level of immune animals, can inhibit too strong cellular immunity reactions, effectively and specifically inhibits inflammation related pathological reactions, and has the advantages of manure technology, low cost, no side effects and easy promotion.

The invention relates to the technical field of biological medicines, in particular to a micromolecular water cluster composition and a preparation method thereof. According to the invention, the micromolecular water cluster composition is prepared from micromolecular water and biological enzyme, and the selected specific biological enzyme can stabilize the micromolecular water for a long time. Meanwhile, the micromolecular water cluster composition prepared by the preparation method disclosed by the invention can be used for promoting keratinocyte end differentiation and up-regulation expression of transcriptional levels of intercellular connexin and keratinocyte envelope protein so as to achieve an effect of enhancing skin barrier, can remarkably improve anti-microbial humoral response,humoral immune response, antibacterial peptide-mediated anti-microbial humoral immune response, bacterial response, bacterial defense response and defense response related genes for other organisms, and has an immune regulation effect.

Provided are an Ebola virus envelope glycoprotein (that is GP protein) codon optimized nucleotide sequence, a human replication deficient recombinant adenovirus capable of expressing the nucleotide sequence, and applications in preparing a vaccine for preventing Ebola virus diseases. The nucleotide sequence takes a replication deficient 5 type adenovirus that is lack of E1 and E3 in a combined mode as a vector. HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and carried protective antigenic genes are codon optimized Zaire type Ebola virus Makona strain envelope glycoprotein genes. After the envelope glycoprotein genes are optimized by codon, the expression level in transfection cells is obviously improved.

The present invention relates to a chimeric antigen, which binds specifically to target cells and enhances multiple immune functions, and the use thereof. Specifically, the present invention relates to: a chimeric antigen for inducing multiple immune functions wherein an immune response-inducing domain and a domain for inducing target cell-specific binding are fused to each other; a pharmaceutical composition for preventing or treating cancer, containing, as an active ingredient, the chimeric antigen for enhancing multiple immune functions; a pharmaceutical composition for preventing or treating infectious disease; a composition for enhancing immunity; and a vaccine composition.

The invention relates to the field of immunology, in particular to a preparation method and application of a chitosan-Pickering emulsion interleukin 12 adjuvant system. Mixing chitosan with water to obtain a water phase; and mixing the water phase with oil phase liquid paraffin, and carrying out ultrasonic treatment to obtain the chitosan-Pickering emulsion. Combining a chitosan-Pickering emulsion with IL-12 to form an adjuvant, and then forming a vaccine with the adjuvant and pORF5. The invention provides a vaccine preparation prepared from a chitosan-Pickering emulsion/IL-12 adjuvant system and chlamydia trachomatis recombinant protein. Experiments prove that the chitosan-Pickering emulsion/IL-12 adjuvant system enhances the humoral immunity and cellular immunity level of an antigen better than those of an antigen without an adjuvant or containing a single adjuvant.